The Orbital Biomanufacturing Opportunity
VALIDATED SCIENCE MEETS MARKET REALITY
500+
Crystallization Studies
Literature demonstrates superior crystal quality in microgravity.
98%
Reduction in Launch Costs
Orbit access from $10k USD/kg in 2010 to $200 USD/kg by 2030.
$653B
Global Biologics Market
Space-manufactured therapeutics represent high-value segment.
20+
Years of Experience
Our team has decades of aerospace and fluid systems expertise.
In-Space Biomanufacturing Capabilities
ORBITAL PRODUCTION SYSTEMS FOR THERAPEUTICS
01. Protein Crystallization
Our systems enable high-quality protein crystals for detailed structural analysis in drug discovery while supporting production-scale therapeutic manufacturing.
02. Cellular Biomanufacturing
Our infrastructure enables three-dimensional cellular structures with enhanced physiological relevance for tissue engineering constructs and cell-based therapeutics.
03. Complex Biologics Production
Our production infrastructure supports monoclonal antibodies, complex protein therapeutics, and novel medications that benefit from microgravity processing advantages unavailable in terrestrial production.
04. Bridging R&D to Production
Our production-scale infrastructure enables pharmaceutical companies to translate decades of ISS research findings into operational manufacturing capabilities.
The Challenge Facing In-Space Biomanufacturing
SCALING FROM MILLILITERS TO LITERS
ISS research has successfully demonstrated microgravity advantages using small-volume systems suitable for scientific investigation. Commercial pharmaceutical production requires fundamentally different capabilities.
Production biomanufacturing requires active transfer of large fluid volumes between multiple process stages—clarification, harvest, formulation, and purification. Research systems process milliliters in contained experiments. Production systems must handle liters in continuous workflows.
Centrifugal Fluid Management for Production-Scale Operations
HOW ORBITAL HELIX ENABLES BREAKTHROUGH SPACE BIOLOGICS
Orbital Helix has developed proprietary centrifugal fluid management technology that unlocks three critical capabilities for pharmaceutical manufacturing in microgravity:
Liters of Production Volume
-
Bridge Small Volume R&D to Production
-
Liter-Scale Fluid Handling in Space
-
Leverage Microgravity at Scale
Continuous Manufacturing Operation
-
High-Throughput Production Workflows
-
Production-Scale Biologics Processing
-
Active Transfers between Processes
Controlled Processing of Biologics
-
Cell Separation and Product Recovery
-
Precise Product Purification
-
Adaptive Centrifugation
Building the Future of Pharmaceutical Manufacturing
PARTNER WITH US
Orbital Helix works with pharmaceutical companies developing advanced therapeutics, space infrastructure providers building commercial orbital platforms, and strategic partners advancing the space pharmaceutical manufacturing ecosystem.
We welcome inquiries from organizations interested in production-scale space biomanufacturing capabilities.